June 20, 2022
1 min watch
Apelian R. Summary #1196574. Offered at: American Headache Society annual scientific assembly; June 9-12, 2022; Denver.
Disclosures: Apelian studies consulting for Lundbeck and AbbVie.
DENVER – Extra information are nonetheless wanted on correct dosing of sufferers with eptinezumab for migraine prevention, Rami Apelian, MD, MPH, FAES, stated on the American Headache Society’s annual scientific assembly.
“There have been some particular person traits [observed in the study], however they didn’t persistently carry over,” Apelian, of Huntington Headache and Neurology in Arcadia, Calif., stated. “What this tells us is that we do have to proceed to individualize remedy, primarily based off of our affected person’s wants.”